ARWR (Arrowhead Pharmaceuticals) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARWR Arrowhead Pharmaceuticals Inc ARWR
49 GF Score
Price $71.92
GF Value $50.62
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

ARWR
49GF Score
Arrowhead Pharmaceuticals Inc ARWR
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of $71.92 is trading 42.1% above its estimated GF Value™ of $50.62. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ARWR:

  • Interest Received:
  • GF Value™: $50.62 vs. price of $71.92 (42.1% above fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for ARWR

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$71.92
Price
$50.62
GF Value